A Phase 1, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI5752 in Japanese Subjects With Advanced Solid Tumors
Latest Information Update: 04 Mar 2025
At a glance
- Drugs Volrustomig (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors AstraZeneca
Most Recent Events
- 28 Feb 2025 Planned End Date changed from 11 Mar 2025 to 31 Mar 2026.
- 03 Jun 2024 Planned End Date changed from 11 Mar 2024 to 11 Mar 2025.
- 20 Jan 2023 New trial record